Stay updated on LN-145 + Pembrolizumab in Transitional Cell Cancer Clinical Trial
Sign up to get notified when there's something new on the LN-145 + Pembrolizumab in Transitional Cell Cancer Clinical Trial page.

Latest updates to the LN-145 + Pembrolizumab in Transitional Cell Cancer Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedFooter revision updated to v3.3.4 (replacing v3.3.3); no changes to study content or page functionality were detected. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check15 days agoNo Change Detected
- Check29 days agoChange DetectedAdded a Locations section showing New York as a study site (Buffalo, NY). Removed the separate New York Locations reference and the HHS Vulnerability Disclosure entry, and updated the page revision to v3.3.3.SummaryDifference0.2%

- Check57 days agoChange DetectedPage revision updated from v3.2.0 to v3.3.2; no substantive content changes observed in the study details page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check65 days agoChange DetectedRemoved the government funding lapse notice from the page, which warned that updates might not be current and that responses could be delayed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check79 days agoChange DetectedNo significant changes were detected; the page content and layout appear unchanged.SummaryDifference0.4%

- Check108 days agoChange DetectedUpdated site notice about funding-related operating status and a new v3.2.0 release; removed the previous v3.1.0 tag.SummaryDifference4%

Stay in the know with updates to LN-145 + Pembrolizumab in Transitional Cell Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the LN-145 + Pembrolizumab in Transitional Cell Cancer Clinical Trial page.